Author Archives: zymecom

← Older posts

Sphere Fluidics expands commercial operations to increase supply of Pico-Surf surfactant for droplet microfluidics

Posted on by zymecom

Investment in resources to meet demand for large-scale supply of patented biocompatible surfactant Pico-Surf offers reliable, highly stable and high-quality droplet generation and processing for microfluidic applications Cambridge, UK, 13 February 2020: Sphere Fluidics, a company commercializing single cell analysis … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

The Native Antigen Company Introduces Novel Coronavirus Antigens

Posted on by zymecom

Newly developed recombinant antigens derived specifically from 2019-nCoV for use in infectious disease research, and assay and vaccine development Oxford, UK, 12 February 2020: The Native Antigen Company, one of the world’s leading suppliers of reagents that enables research into … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

ERS Genomics and Aelian Biotechnology announce CRISPR/Cas9 license agreement enabling Aelian’s unique screening platform

Posted on by zymecom

DUBLIN, Ireland, and VIENNA, Austria, 11 February 2020: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Aelian Biotechnology (“Aelian”) today announced the signing of a license … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

ERS Genomics provides comment on affirmation of key CRISPR-Cas9 patent involved in European opposition proceedings  

Posted on by zymecom

DUBLIN, Ireland, 10 February 2020 – ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier, announced today that the European Patent Office (EPO) has rejected arguments filed in … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer

Posted on by zymecom

Dr Morris will lead Enterprise’s therapeutics development strategy and drive the Company’s two lead respiratory programmes through the clinic Brighton, UK, 10 February 2020: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

ELRIG UK and British Pharmacological Society appoint Dr Ann Hayes to chair joint steering committee

Posted on by zymecom

Renowned drug discovery leader to guide alliance formed to improve scientific exchange in UK drug discovery community York and London, UK, 5 February 2020: The European Laboratory Research & Innovation Group (ELRIG) UK and the British Pharmacological Society, today announced … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

Start Codon joins Cancer Research UK’s Entrepreneurial Programmes Initiative

Posted on by zymecom

Aims to support the next generation of oncology-based start-ups Start Codon to focus on Cambridge, UK, research community, supporting new businesses that will address unmet medical needs CAMBRIDGE and LONDON, UK, 05 February 2020 – Start Codon, a new model … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

The Native Antigen Company Introduces Antigen and Antibody Conjugation Kits

Posted on by zymecom

Highly scalable kits enable researchers to prepare liquid-stable antigen and antibody conjugates with a wide range of labels including enzymes, fluorochromes, and biotin Oxford, UK, 4 February 2020: The Native Antigen Company, one of the world’s leading suppliers of reagents … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

Lab of the Future Congress USA, 19–20th May 2020, Boston MA

Posted on by zymecom

USA congress showcasing research innovation in the life sciences Follows successful European event in Cambridge, UK Cambridge, UK, and Boston, MA, USA, 03 February 2020: Open Pharma Research, a platform for information exchange and networking in the life sciences, today … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment

PhoreMost strengthens leadership team with two key appointments

Posted on by zymecom

Dr Catherine Beech, OBE, joins Board as a Non-Executive Director Dr Benedict Cross joins as Senior Director (Technology) Cambridge, UK, 03 February 2020: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has made … Continue reading

Posted in News from Zyme and the companies we work with | Leave a comment ← Older posts
  • People

    An experienced senior team of specialists in life science communications, with expertise gained in-house and agency side, offering the flexibility to support both early-stage companies and large multinationals.

  • Keep in touch

    +44(0) 1223 968 920

    info@zymecommunications.com


     

  • Upcoming Events

    Zyme Communications will be providing support for its clients attending the following events:

    BioProcess International Asia

    When: Wed February 26 09:00 - Fri February 28 18:00
    Where: Kyoto, Japan

    Molecular Medicine Tri-Conference

    When: Sun March 1 09:00 - Wed March 4 18:00
    Where: San Francisco, USA